You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrifluoperazine
Accession NumberDB00831  (APRD00173, DB08616)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]
Structure
Thumb
Synonyms
10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine
Trifluoperazina
Trifluoperazine
Trifluoperazinum
Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Trifluoroperazine
Trifluperazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-flurazine Tab 1mgTablet1.18 mgOralNovopharm Limited1971-12-311996-09-10Canada
Novo-flurazine Tab 20mgTablet23.6 mgOralNovopharm Limited1971-12-311996-09-10Canada
Novo-trifluzine - Tab 10mgTablet11.8 mgOralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 2mgTablet2.36 mgOralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 5mgTablet5.9 mgOralNovopharm Limited1971-12-312013-06-03Canada
PMS Trifluoperazine HCl Syrup 11.8mg/mlSyrup10 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 10mgTablet10 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 1mgTablet1 mgOralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 20mgTablet20 mgOralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 2mgTablet2 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 5mgTablet5 mgOralPharmascience Inc1988-12-312012-03-14Canada
PMS-trifluoperazine HCl Syr 1.18mg/mlSyrup1 mgOralPharmascience Inc1988-12-312012-10-17Canada
Stelazine Tab 10mgTablet10 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 1mgTablet1 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 2mgTablet2 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-312000-10-18Canada
Stelazine Tab 5mgTablet5 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-09-28Canada
Terfluzine ConcentrateSyrup10 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312011-08-03Canada
Terfluzine-1Tablet1 mgOralValeant Canada Lp Valeant Canada S.E.C.1974-12-312011-08-03Canada
Terfluzine-10Tablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.1973-12-312011-08-03Canada
Terfluzine-2Tablet2 mgOralValeant Canada Lp Valeant Canada S.E.C.1978-12-312011-08-03Canada
Terfluzine-5Tablet5 mgOralValeant Canada Lp Valeant Canada S.E.C.1968-12-312011-08-03Canada
TrifluoperazineTablet5 mgOralAa Pharma Inc1975-12-31Not applicableCanada
TrifluoperazineTablet20 mgOralAa Pharma Inc1984-12-31Not applicableCanada
TrifluoperazineTablet2 mgOralAa Pharma Inc1975-12-31Not applicableCanada
TrifluoperazineTablet10 mgOralAa Pharma Inc1975-12-31Not applicableCanada
TrifluoperazineTablet1 mgOralAa Pharma Inc1975-12-31Not applicableCanada
Trifluoperazine 10mg TabletsTablet10 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 1mg TabletsTablet1 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 2mg TabletsTablet2 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 5mg TabletsTablet5 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine Tab 10mgTablet10 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 10mgTablet10 mgOralPro Doc Limitee1977-12-312010-07-13Canada
Trifluoperazine Tab 1mgTablet1 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 1mgTablet1 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Trifluoperazine Tab 2mgTablet2 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Trifluoperazine Tab 2mgTablet2 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 5mgTablet5 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 5mgTablet5 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrifluoperazineTablet, film coated2 mg/1OralSTAT Rx USA LLC1981-11-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralREMEDYREPACK INC.2007-04-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralREMEDYREPACK INC.2008-05-06Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-05-11Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated2 mg/1OralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-08-22Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralREMEDYREPACK INC.2012-09-27Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated5 mg/1OralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine HydrochlorideTablet1 mg/1OralREMEDYREPACK INC.2011-12-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EskazineNot Available
EskazinylNot Available
JatroneuralNot Available
ModalinaNot Available
StelazineNot Available
TerfluzineNot Available
TrifluoperazNot Available
TriftazinNot Available
Brand mixtures
NameLabellerIngredients
Stelabid ForteGlaxosmithkline Inc
Stelabid No 1Glaxosmithkline Inc
Stelabid No 2Glaxosmithkline Inc
Salts
Name/CASStructureProperties
Trifluoperazine Hydrochloride
440-17-5
Thumb
  • InChI Key: BXDAOUXDMHXPDI-UHFFFAOYSA-N
  • Monoisotopic Mass: 479.117658566
  • Average Mass: 480.417
DBSALT000569
Categories
UNII214IZI85K3
CAS number117-89-5
WeightAverage: 407.496
Monoisotopic: 407.164303088
Chemical FormulaC21H24F3N3S
InChI KeyZEWQUBUPAILYHI-UHFFFAOYSA-N
InChI
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Pharmacology
IndicationFor the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Structured Indications
PharmacodynamicsTrifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionTrifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Neuron-specific vesicular protein calcyonProteinyes
antagonist
HumanQ9NYX4 details
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
CalmodulinProteinunknown
inhibitor
HumanP62158 details
Troponin C, slow skeletal and cardiac musclesProteinunknownNot AvailableHumanP63316 details
Protein S100-A4Proteinunknown
inhibitor
HumanP26447 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-20 hours
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineTrifluoperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTrifluoperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Trifluoperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Trifluoperazine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Trifluoperazine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Trifluoperazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trifluoperazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Trifluoperazine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trifluoperazine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Trifluoperazine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.Approved, Illicit, Investigational
AlprenololTrifluoperazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Trifluoperazine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Trifluoperazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amperozide.Experimental
AmphetamineTrifluoperazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Trifluoperazine may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Trifluoperazine.Approved
ApomorphineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aripiprazole.Approved, Investigational
ArotinololTrifluoperazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Trifluoperazine.Approved, Investigational
ArtemetherThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Trifluoperazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Trifluoperazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Trifluoperazine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Trifluoperazine.Approved
AtovaquoneThe serum concentration of Trifluoperazine can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azaperone.Vet Approved
AzelastineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azelastine.Approved
AzithromycinThe metabolism of Trifluoperazine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.Illicit
BefunololTrifluoperazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzocaine.Approved
BenzphetamineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
BetaxololTrifluoperazine may increase the hypotensive activities of Betaxolol.Approved
Betulinic AcidThe serum concentration of Trifluoperazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololTrifluoperazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideTrifluoperazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololTrifluoperazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Trifluoperazine.Approved
BopindololTrifluoperazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe metabolism of Trifluoperazine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trifluoperazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brotizolam.Approved, Withdrawn
BucindololTrifluoperazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolTrifluoperazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.Approved, Investigational
BupranololTrifluoperazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluoperazine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Trifluoperazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trifluoperazine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Trifluoperazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Trifluoperazine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Trifluoperazine.Approved
CarbamazepineThe metabolism of Trifluoperazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Trifluoperazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.Approved
CarteololTrifluoperazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolTrifluoperazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololTrifluoperazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Trifluoperazine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Trifluoperazine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluoperazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.Approved
ChlorphentermineTrifluoperazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Trifluoperazine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trifluoperazine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Trifluoperazine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Trifluoperazine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Trifluoperazine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Trifluoperazine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Trifluoperazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Trifluoperazine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Trifluoperazine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Trifluoperazine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.Approved, Illicit
ClotrimazoleThe metabolism of Trifluoperazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Trifluoperazine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Trifluoperazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trifluoperazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trifluoperazine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Trifluoperazine.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Trifluoperazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Trifluoperazine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Trifluoperazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Trifluoperazine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Trifluoperazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Trifluoperazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluoperazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Trifluoperazine can be increased when it is combined with Dapsone.Approved, Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Trifluoperazine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Trifluoperazine.Approved
DeferasiroxThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Trifluoperazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trifluoperazine.Approved, Vet Approved
DextroamphetamineTrifluoperazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluoperazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trifluoperazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Trifluoperazine.Approved, Illicit, Vet Approved
DiethylpropionTrifluoperazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trifluoperazine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Trifluoperazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trifluoperazine.Approved
DihydroartemisininThe serum concentration of Trifluoperazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Trifluoperazine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Trifluoperazine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Trifluoperazine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Trifluoperazine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Trifluoperazine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trifluoperazine.Approved, Investigational
DoxycyclineThe serum concentration of Trifluoperazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluoperazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trifluoperazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Trifluoperazine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trifluoperazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Trifluoperazine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trifluoperazine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.Approved, Investigational
EsmololTrifluoperazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Trifluoperazine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Trifluoperazine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trifluoperazine.Approved
EthanolTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trifluoperazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluoperazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Trifluoperazine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Trifluoperazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Trifluoperazine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Trifluoperazine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Trifluoperazine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Trifluoperazine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Trifluoperazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Trifluoperazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Trifluoperazine.Approved
GepironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Trifluoperazine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Trifluoperazine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trifluoperazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Trifluoperazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.Approved
HydrocodoneTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.Approved, Illicit
Hydroxyamphetamine hydrobromideTrifluoperazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Trifluoperazine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Trifluoperazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Trifluoperazine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Trifluoperazine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Trifluoperazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.Investigational, Withdrawn
IndenololTrifluoperazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Trifluoperazine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Trifluoperazine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Trifluoperazine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trifluoperazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trifluoperazine.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Trifluoperazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Trifluoperazine.Approved, Investigational
LabetalolTrifluoperazine may increase the hypotensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Trifluoperazine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Trifluoperazine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Trifluoperazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trifluoperazine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Trifluoperazine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Trifluoperazine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Trifluoperazine.Approved, Investigational
LevobunololTrifluoperazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Trifluoperazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Trifluoperazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levorphanol.Approved
LidocaineThe metabolism of Trifluoperazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Trifluoperazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Trifluoperazine.Approved, Investigational
LisdexamfetamineTrifluoperazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Trifluoperazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Trifluoperazine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lu AA21004.Investigational
LumefantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Trifluoperazine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melperone.Approved
MephedroneTrifluoperazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTrifluoperazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.Approved, Illicit
MequitazineTrifluoperazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTrifluoperazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trifluoperazine.Approved
MethotrimeprazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
MetipranololTrifluoperazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Trifluoperazine.Approved, Investigational
MetyrosineTrifluoperazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Trifluoperazine can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Trifluoperazine.Approved
MirtazapineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Trifluoperazine.Approved, Investigational
MizoribineThe serum concentration of Trifluoperazine can be increased when it is combined with Mizoribine.Investigational
MMDATrifluoperazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Trifluoperazine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trifluoperazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Trifluoperazine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trifluoperazine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Trifluoperazine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Trifluoperazine.Approved
NevirapineThe metabolism of Trifluoperazine can be decreased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Trifluoperazine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Trifluoperazine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Trifluoperazine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Trifluoperazine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Trifluoperazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Trifluoperazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Trifluoperazine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Opium.Approved, Illicit
OrphenadrineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Trifluoperazine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluoperazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Trifluoperazine.Approved, Investigational
ParaldehydeTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.Approved
Peginterferon alfa-2bThe serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololTrifluoperazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trifluoperazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.Approved
PhenobarbitalThe metabolism of Trifluoperazine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenoxyethanol.Approved
PhentermineTrifluoperazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.Approved
PindololTrifluoperazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Trifluoperazine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Trifluoperazine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Trifluoperazine.Approved
PractololTrifluoperazine may increase the hypotensive activities of Practolol.Approved
PramipexoleTrifluoperazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Trifluoperazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Trifluoperazine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trifluoperazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trifluoperazine.Approved
PrimaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Trifluoperazine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trifluoperazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluoperazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
ProguanilThe serum concentration of Trifluoperazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trifluoperazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trifluoperazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Trifluoperazine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trifluoperazine.Approved
PSD502The risk or severity of adverse effects can be increased when Trifluoperazine is combined with PSD502.Investigational
PseudoephedrineTrifluoperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Trifluoperazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Trifluoperazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Trifluoperazine.Approved
QuinacrineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Trifluoperazine.Approved
QuinidineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Trifluoperazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Trifluoperazine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trifluoperazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Trifluoperazine.Approved
RifampicinThe metabolism of Trifluoperazine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trifluoperazine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Trifluoperazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ritanserin.Investigational
RitobegronTrifluoperazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Trifluoperazine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Trifluoperazine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Trifluoperazine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Trifluoperazine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Romifidine.Vet Approved
RopiniroleTrifluoperazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine.Approved
RotigotineTrifluoperazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trifluoperazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Trifluoperazine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Trifluoperazine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluoperazine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Trifluoperazine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Trifluoperazine.Approved
SinefunginThe serum concentration of Trifluoperazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Trifluoperazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Trifluoperazine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Trifluoperazine.Approved, Investigational
SotalolTrifluoperazine may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Trifluoperazine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Trifluoperazine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.Approved, Investigational
SulfadoxineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Trifluoperazine.Approved, Investigational
SuvorexantTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Trifluoperazine.Approved, Investigational
tafenoquineThe serum concentration of Trifluoperazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Trifluoperazine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Trifluoperazine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Trifluoperazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Trifluoperazine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Trifluoperazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Trifluoperazine.Approved
TenofovirThe metabolism of Trifluoperazine can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrodotoxin.Investigational
ThalidomideTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Trifluoperazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trifluoperazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Trifluoperazine.Approved
TiclopidineThe metabolism of Trifluoperazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Trifluoperazine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Trifluoperazine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trifluoperazine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Trifluoperazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Trifluoperazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trifluoperazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Trifluoperazine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Trifluoperazine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trifluoperazine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Trifluoperazine.Approved
VemurafenibThe serum concentration of Trifluoperazine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Trifluoperazine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Trifluoperazine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Trifluoperazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Trifluoperazine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Trifluoperazine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Trifluoperazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Trifluoperazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluoperazine.Approved, Investigational
ZolpidemTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AB06
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9814
Caco-2 permeable+0.6856
P-glycoprotein substrateSubstrate0.8529
P-glycoprotein inhibitor IInhibitor0.9058
P-glycoprotein inhibitor IIInhibitor0.9089
Renal organic cation transporterInhibitor0.6842
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9109
CYP450 3A4 substrateNon-substrate0.594
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.5618
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8247
Ames testNon AMES toxic0.8944
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9327
hERG inhibition (predictor II)Inhibitor0.8556
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Sandoz inc
  • Wockhardt eu operations (swiss) ag
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral1.18 mg
TabletOral23.6 mg
TabletOral11.8 mg
TabletOral2.36 mg
TabletOral5.9 mg
SyrupOral1 mg
TabletOral
SyrupOral10 mg
TabletOral1 mg
TabletOral10 mg
TabletOral2 mg
TabletOral20 mg
TabletOral5 mg
TabletOral1 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Trifluoperazine HCl 10 mg tablet1.7USD tablet
Trifluoperazine 10 mg tablet1.63USD tablet
Trifluoperazine HCl 5 mg tablet1.09USD tablet
Trifluoperazine 5 mg tablet1.08USD tablet
Trifluoperazine HCl 2 mg tablet0.89USD tablet
Trifluoperazine 2 mg tablet0.86USD tablet
Trifluoperazine HCl 1 mg tablet0.59USD tablet
Trifluoperazine 1 mg tablet0.58USD tablet
Apo-Trifluoperazine 20 mg Tablet0.58USD tablet
Apo-Trifluoperazine 10 mg Tablet0.29USD tablet
Apo-Trifluoperazine 5 mg Tablet0.24USD tablet
Apo-Trifluoperazine 2 mg Tablet0.18USD tablet
Apo-Trifluoperazine 1 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility12.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.03HANSCH,C ET AL. (1995)
logS-4.52ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00876 mg/mLALOGPS
logP4.87ALOGPS
logP4.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity110.98 m3·mol-1ChemAxon
Polarizability41.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03kc-9740000000-e505b8906d154e2285a4View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Lahti RA, Evans DL, Stratman NC, Figur LM: Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol. 1993 Jun 4;236(3):483-6. [PubMed:8102973 ]
  4. Schmidt MH, Lee T: Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure. Psychiatry Res. 1991 Mar;36(3):319-28. [PubMed:1676523 ]
  5. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
  6. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Clathrin light chain binding
Specific Function:
Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
Gene Name:
CALY
Uniprot ID:
Q9NYX4
Molecular Weight:
23433.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467 ]
  3. Madrid PB, Polgar WE, Toll L, Tanga MJ: Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3014-7. Epub 2007 Mar 24. [PubMed:17407813 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fujinaga M, Hoffman BB, Baden JM: Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos. Dev Biol. 1994 Apr;162(2):558-67. [PubMed:8150214 ]
  4. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Torres-Piedra M, Figueroa M, Hernandez-Abreu O, Ibarra-Barajas M, Navarrete-Vazquez G, Estrada-Soto S: Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches. Bioorg Med Chem. 2011 Jan 1;19(1):542-6. doi: 10.1016/j.bmc.2010.10.063. Epub 2010 Nov 4. [PubMed:21129983 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Troponin t binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC1
Uniprot ID:
P63316
Molecular Weight:
18402.36 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Rage receptor binding
Specific Function:
Not Available
Gene Name:
S100A4
Uniprot ID:
P26447
Molecular Weight:
11728.41 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Malashkevich VN, Dulyaninova NG, Ramagopal UA, Liriano MA, Varney KM, Knight D, Brenowitz M, Weber DJ, Almo SC, Bresnick AR: Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8605-10. doi: 10.1073/pnas.0913660107. Epub 2010 Apr 26. [PubMed:20421509 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
conversion inhibitor
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular Weight:
146422.99 Da
References
  1. Hirata Y, Ishii K, Taguchi T, Suita S, Takeshige K: Conversion of xanthine dehydrogenase to xanthine oxidase during ischemia of the rat small intestine and the effect of trifluoperazine on the conversion. J Pediatr Surg. 1993 Apr;28(4):597-600. [PubMed:8483075 ]
  2. Greene EL, Paller MS: Calcium and free radicals in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol. 1994 Jan;266(1 Pt 2):F13-20. [PubMed:8304479 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO: Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009 Sep;37(9):1948-55. doi: 10.1124/dmd.109.028225. Epub 2009 Jun 1. [PubMed:19487247 ]
  2. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, Yokoi T: Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos. 2007 Oct;35(10):1781-7. Epub 2007 Jul 9. [PubMed:17620344 ]
  3. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO: Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos. 2006 Mar;34(3):449-56. Epub 2005 Dec 28. [PubMed:16381668 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23